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ABSTRACT All inherited forms of human prion diseases are linked with mutations in the prion protein (PrP) gene. Here we
have investigated the stability and Cu(II) binding properties of three recombinant variants of murine full-length PrP(23–231)-
containing destabilizing point mutations that are associated with human Gerstmann-Stra¨ussler-Scheinker disease (F198S),
Creutzfeld-Jakob disease (E200K), and fatal familial insomnia (D178N) by electron paramagnetic resonance and circular
dichroism spectroscopy. Furthermore, we analyzed the variants H140S, H177S, and H187S of the isolated C-terminal domain
of murine PrP, mPrP(121–231), to test a role of the histidine residues in Cu(II) binding. The F198S and E200K variants of
PrP(23–231) differed in Cu(II) binding from the wild-type mPrP(23–231). However, circular dichroism spectroscopy indicated
that the variants and the wild type did not undergo conformational changes in the presence of Cu(II). The D178N variant showed
a high tendency to aggregate at pH 7.4 both with and without Cu(II). At lower pH values, it showed the same Cu(II) binding
behavior as the wild type. The analysis allowed for a better location of the Cu(II) binding sites in the C-terminal part of the
protein. Our present data indicate that hereditary forms of prion diseases cannot be rationalized on the basis of altered Cu(II)
binding or mutation-induced protein destabilization alone.
INTRODUCTION
Transmissible spongiform encephalopathies (TSEs) such
as bovine spongiform encephalopathy (BSE) in cattle and
Creutzfeldt-Jakob disease (CJD) in humans are supposed to
be caused by the scrapie form of prion protein (PrPSc), the
abnormal, oligomeric form of the cellular prion protein
(PrPC) of the host. Both forms of prion protein (PrP) appear
to have identical covalent structures but differ in tertiary
structure and oligomerization state (Grifﬁth, 1967; Prusiner,
1982, 1991).
PrPC is a glycosyl phosphatidylinositol-anchored cell-
surface glycoprotein that is strongly expressed in cells of the
central nervous system (Kretzschmar et al., 1986; Stahl et al.,
1987; Stahl et al., 1990). It consists of 209 amino acids and is
covalently modiﬁed by the addition of several high-mannose
glycans (Endo et al., 1989). In contrast, PrPSc is an insoluble,
proteinase K-resistant oligomer of PrP that accumulates in
the brain during infection with prions (Weissmann et al.,
1996).
Evidently, full insight into prion propagation requires
knowledge of the three-dimensional structures of PrPC and
PrPSc and the mechanism of formation of PrPSc from PrPC
(Jarrett and Lansbury, 1993; Prusiner, 1991). The de-
termination of the NMR structure of recombinant PrPC from
several organisms including mice (Riek et al., 1996; Riek
et al., 1997), hamsters (Donne et al., 1997), cattle (Lopez
Garcia et al., 2000), and humans (Zahn et al., 2000) has
shown that PrPC consists of a well-structured C-terminal
domain comprising residues 121–231 and a ﬂexibly disor-
dered N-terminal region (residues 23–120). The C-terminal
domain PrP(121–231) contains three a-helices and a two-
stranded, antiparallel b-sheet. The only two cysteine residues
of the protein, Cys-179 and Cys-214, form a buried disul-
ﬁde bridge connecting helices 2 and 3. Unfortunately, the
tendency of PrPSc to form insoluble aggregates has so far
prevented its structure determination at the atomic level.
However, Fourier transform infrared (FTIR) spectroscopy
showed that PrPSc has an increased b-sheet content com-
pared to PrPC (Pan et al., 1993).
More than 20 different mutations in the prion protein are
known to be associated with inherited TSEs in humans
(Collinge, 2001), i.e., the inherited form of CJD (Bell and
Ironside, 1993; Spudich et al., 1995), the Gerstmann-
Stra¨ussler-Scheinker syndrome (GSS; Ghetti et al., 1995;
Unverzagt et al., 1997), and fatal familial insomnia (FFI;
Goldfarb et al., 1992; Gambetti et al., 1995). Interestingly, all
disease-related point mutations in human PrP are located
within segment 90–231, which forms the protease-resistant
core of the PrPSc oligomer (Safar et al., 1990, Weissmann
et al., 1996). Nevertheless, the mechanistic role of mutations
in spontaneous formation of PrPSc in inherited TSEs is not
evident. It is however quite evident that neither destabiliza-
tion of PrPC nor higher stability of PrPSc are general
mechanisms underlying the spontaneous generation of
prions in patients with inherited TSEs (Prusiner, 1997;
Cohen et al., 1994; Huang et al., 1994; Liemann and
Glockshuber, 1999; Swietnicki et al., 1998).
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A number of recent observations indicate that PrP may be
a metalloprotein in vivo. It has been claimed that the levels of
copper in the brains of prion-protein-knockout (PrP0/0) mice
are lower than in wild-type mice (Brown et al., 1997),
although this ﬁnding has not been reproduced by other
workers (Waggoner et al., 2000). Furthermore, PrP has also
been proposed to function as a copper-transport protein
(Pauly and Harris, 1998). In vitro studies have shown that
synthetic peptides containing the octarepeat part of the N-
terminal region of PrP (a fourfold repeat of eight amino acids
with the consensus sequence PHGGGWGQ) bind 1–6 Cu(II)
ions (Brown et al., 1997; Hornshaw, McDermott, and Candy,
1995; Hornshaw et al., 1995; Sto¨ckel et al., 1998; Viles et al.,
1999; Miura et al., 1999; Aronoff-Spencer et al., 2000;
Cereghetti et al., 2001; Burns et al., 2002; Qin et al., 2002).
Although Cu(II) binding was long thought to take place only
in the octarepeat region of PrPC, recent ﬁndings indicate that
additional Cu(II) bindings are present in the more C-terminal
segments. Fluorescence titration showed that recombinant
human PrP(91–231) has a high-afﬁnity Cu(II) binding site
located in the region around His-96 and His-123 and weaker
binding upstream of this region (Jackson et al., 2001). Cu(II)
binding at pH 8 involving His-96 and His-111 was shown
using x-ray absorption ﬁne-structure spectrometry (Hasnain
et al., 2001). In our earlier electron paramagnetic resonance
(EPR) studies, we also showed that the structured C-terminal
domain of murine PrP(23–231) is able to interact with Cu(II)
ions (Cereghetti et al., 2001; Van Doorslaer et al., 2001).
Three pH-dependent Cu(II)-coordination types are observed
in the isolated mPrP(121–231) domain (Cereghetti et al.,
2001). Binding of one Cu(II) ion to the C-terminal region of
PrP at physiological concentrations was also found by
Kramer et al. (2001).
To investigate a possible relationship between metal
binding and disease, we analyzed by EPR spectroscopy the
binding of Cu(II) to three recombinant mPrP(23–231)
variants that correspond to the three different phenotypes
of inherited human prion diseases (Fig. 1 a): D178N (with
M129V, FFI), F198S (GSS), and E200K (inherited CJD).
We ﬁnd that two of the mPrP(23–231) variants partially
show anomalous Cu(II) binding behavior compared to the
wild type. Furthermore, equilibrium unfolding transitions of
these variants of full-length PrP(23–231) showed different
degrees of destabilization. Additionally, the recombinant
histidine replacement variants H140S, H177S, and H187S of
mPrP(121–231) were investigated to identify the histidine-
related Cu(II) binding sites (Fig. 1 a).
MATERIALS AND METHODS
Plasmids and oligonucleotides
used for site-directed mutagenis
The mPrP(23–231) variants D178N, E200K, and F198S were puriﬁed from
cytoplasmic Escherichia coli inclusion bodies as described previously
(Liemann and Glockshuber, 1999). The mPrP(23–231) D178N variant had
methionine at position 129.
For construction and expression of the histidine-to-serine mutants of
mPrP(121–231), the previously described phagemid pPrP-CRR was used
(Hornemann and Glockshuber, 1996). Site-directed mutagenesis was
performed according to the methods of Kunkel (Kunkel, 1985; Kunkel
et al., 1991) using uridinylated single-stranded pPrP-CRR from M13K07
phage infection of the E. coli strain CJ236 with oligonucleotide primers (59-
CCAATCATTGCCAA AAGATCATGGGTCGACT-39) for His140Ser,
(59-AAT ATTGACGCAGTCGCTCACGAAGTTGTTCTG-39) for
His177Ser, and (59-CGTCGTGGTGACCGTCGACTGCTTAATGGT-39)
for His187Ser. Successful mutagenesis was veriﬁed by dideoxynucleotide
sequencing of the entire PrP genes.
Protein puriﬁcation
Recombinant mPrP(23–231) and its mutants D178N, E200K, and F198S
were puriﬁed as described (Liemann and Glockshuber, 1999). After
puriﬁcation, the proteins were dialyzed against distilled water and stored
at 208C after being frozen in liquid nitrogen. The puriﬁcation of the
histidine variants was also performed in accordance with the puriﬁcation
protocol established for the wild-type PrP(121–231) as previously described
(Liemann and Glockshuber, 1999). The molecular mass of the puriﬁed
mutants was conﬁrmed by matrix-assisted ultraviolet (UV) laser desorption/
ionization (MALDI) mass spectrometry. Circular dichroism (CD) spectra of
FIGURE 1 (a) Three-dimensional structure
of the folded C-terminal domain of PrP
(PrP(121–231)) showing the location of the
amino acid residues mutated in the prion
protein variants analyzed in this study. (b)
Magniﬁcation of the histidine 187 environment
in the three-dimensional fold of the murine
prion protein PrP(121–231).
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the mutants conﬁrmed that they folded correctly and had a tertiary structure
similar to that of the wild-type protein. The puriﬁcation yields were in the
range of 10–13 mg of pure protein per liter of bacterial culture for the
His140Ser and His177Ser mutants, and only 0.2 mg/l of bacterial culture for
the His187Ser mutant. The puriﬁcation of the His187Ser variant from
periplasmic inclusion bodies was unsuccessful.
Protein concentrations
Protein concentrations were determined by the speciﬁc absorbance of the
proteins with the extinction coefﬁcient (e) ¼ 19,890 M1  cm1 for
mPrP(121–231) and e ¼ 62,280 M1  cm1 for mPrP(23–231) (Gill and
von Hippel, 1989).
Sample preparation for pH-dependent
EPR measurements
These buffers were used (10 mM each): formic acidNaOH (pH 4.0), sodium
cacodylateHCl (pH 6.0), and 3-(N-morpholino)propane-sulfonic acid
(MOPS) NaOH (pH 7.4). For the measurements of the Cu(II) binding of
wild-type, D178N, E200K, and F198S mPrP(23–231) at the different pH
values, 2, 4, and 10 molar equivalents of CuCl2 were added to 0.1 mM of the
peptide in 10 mM buffer. For the histidine mutants, one to four molar
equivalents of CuCl2 were added to 0.1 mM protein solutions. In most cases,
aggregation took place as described (see Results).
Samples for CD spectra
A stock solution of mPrP(23–231) wild type or variants was used to prepare
samples of 10 mM PrP(23–231) with or without 0.1 mM CuCl2 in distilled
water without buffer or with 10 mM formic acid/NaOH, pH 4.0.
EPR spectroscopy
The EPR spectra were recorded on a Bruker ESP300 spectrometer
(microwave frequency, 9.43 GHz) equipped with an ER4131 VT digital
temperature-control system, making use of gaseous nitrogen as a coolant. A
microwave power of 20 mW, a modulation amplitude of 0.5 mT, and
a modulation frequency of 100 kHz were used. All spectra were recorded at
a temperature of 120 K. The EPR spectra were simulated using the EasySpin
program, a MATLAB toolbox developed for EPR simulations (see http://
www.esr.ethz.ch).
CD spectra
Far-UV CD spectra were measured at 228C on a Jasco 710 CD
spectropolarimeter in 0.1-cm quartz cuvettes, accumulated eight times and
corrected for the corresponding buffer. Protein samples were centrifuged
(5 min, 14,000 rpm, 258C) before the concentration and CD measurements
to remove possible aggregates.
Equilibrium-folding transition studies
The thermodynamic stability of PrP wild type and mutants D178N, F198S,
and E200K of both murine PrP(23–231) and PrP(121–231) was analyzed by
measuring the CD signal at 222 nm. Urea concentrations of 0–9Mwere used
as denaturant. The buffer used at pH 7.0 was 45 mM sodium phosphate/
NaOH, whereas 50 mM formic acid/NaOH was used at pH 4.0. In addition
to these measurements at low ionic strength, another set of experiments was
performed at medium ionic strength (135 mM NaCl additionally added to
the solutions of mPrP(23–231) and 50 mM NaCl to the solutions of
mPrP(121–231)). Medium ionic strength is essential for the formation of the
unfolding intermediate of PrP observed at acidic pH (Hornemann and
Glockshuber, 1998; Ceregetti et al., in preparation). The protein concentra-
tion of both wild-type and mutant proteins was 30 mM for mPrP(23–231)
and 20 mM for mPrP(121–231). All transitions were recorded at 228C.
RESULTS
Figs. 2, 3, and 4 show the X-band EPR spectra of the
mPrP(23–231) variants E200K, F198S, and D178N (Fig. 1
a) in the presence of four molar equivalents of Cu2þ at pH
values 4, 6, and 7.4 together with the corresponding spectra
of the Cu(II)-bound wild-type protein and the buffer/Cu(II)
solutions. The EPR spectra are typical for Cu(II) type-2
complexes (axial g matrix, copper hyperﬁne interaction,
Ak[400MHz). Type-2 complexes are largely square-planar
with a possible ﬁfth weak coordination. When the EPR data
of different known type-2 copper complexes are plotted in
a gk vs. Ak graph, a correlation can be found between these
values and the nature of the four equatorial ligands (Peisach
and Blumberg, 1974). Depending on the type of the
equatorially coordinating atoms, the gk and Ak values fall
within speciﬁc regions. Unfortunately, these regions are
overlapping partially, and the gk and Ak values depend
also on the charge of the surrounding ligands and the
possible ﬁfth ligand, so that a clear-cut determination of
the coordination sphere on the basis of the EPR data alone
is not possible. Nevertheless, these parameters can be used
to get a ﬁrst idea about the coordinating atoms.
pH-dependent Cu(II) binding to wild-type
mPrP(23–231)
Three Cu(II) coordination types are observed for the wild-
type mPrP(23–231) in the pH range of 3–8 (spectra of
complexes 1 to 3 in Figs. 2 b, 3 b, and 4 b) (Cereghetti et al.,
2001). The EPR spectra are clearly different from those of
the Cu(II)/buffer solutions (Figs. 2 a, 3 a, and 4 a). The EPR
parameters characterizing complexes 1–3 are given in Table 1
(Cereghetti et al., 2001; Van Doorslaer et al., 2001).
Complexes 1 (pH 3–6) and 2 (pH 3–8) could be related to the
C-terminal part of mPrP(121–231), whereas the third mode
of Cu(II) complexation (complex 3, pH 7–8) is observed in
Cu(II)-bound mPrP(121–231), mPrP(58–91), and mPrP
(23–231).
At pH values of 4 and 6, up to four molar equivalents of
CuCl2 could be added to the full-length protein without
signiﬁcant change in the EPR spectrum other than its
intensity (Cereghetti et al., 2001). At higher concentrations of
Cu2þ, the EPR spectrum was either distorted (appearance of
complex 5, unspeciﬁc binding) and/or the EPR spectrum
of the Cu(II)-bound buffer was found. The appearance of
two contributions to the EPR spectra at these pH values
(complexes 1 and 2) indicated that at least two speciﬁc
binding sites are present in the C-terminal part of the protein.
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The fact that up to four equivalents of Cu2þ could be added
without spectral changes can be explained in two ways:
either additional EPR-silent binding of Cu(II) occurs (protein
or non-protein related) or there are four Cu(II) binding sites
in the C-terminal part of the protein with some of them
having very similar EPR characteristics. Upon variation of
the pH value from 3 to 6, the EPR contribution of complex 1
was found to decrease as the spectrum of complex 2
increased. This indicates that the Cu(II) binding capacity of
the two sites is pH dependent, but it is not a clear proof that
site 1 evolves into site 2. The sudden appearance of site 3 at
pH 7 whereby site 2 remains present seems to exclude an
evolvement of 2 into 3. At pH values$ 7, aquo Cu2þ is only
sparingly soluble and precipitates as EPR silent [Cu(OH)2]n.
Any excess of Cu2þ does not introduce interference in the
EPR spectra, but makes a determination of the Cu2þ/protein
ratio difﬁcult. In the following, the EPR spectra of the
different proteins with four molar equivalents of CuCl2 are
shown unless aggregation of the protein took place. As
mentioned in the experimental part, control experiments
were performed with varying molar equivalents.
The CD spectra of wild-type mPrP(23–231) without Cu2þ
and after addition of 4 and 10 molar equivalents of Cu2þ at
the different pH values show that the shape of the spectra
does not change upon addition of Cu2þ, which suggests that
no substantial change in protein conformation has occurred
(see Supplementary material at http://www.biophysj.org/
content/vol84/issue3/ ).
pH-dependent Cu(II) binding to D178N, E200K,
and F198S mPrP(23–231)
The EPR spectra of Cu(II)-bound E200K mPrP(23–231) at
pH values of 4 and 6 (Figs. 2 c and 3 c) are the same as those
obtained for the Cu(II)-bound wild-type protein at these pH
values (Figs. 2 b and 3 b). However, at pH 7.4, only complex
2 is visible (Fig. 4, c and c9), and complex 3 is missing
completely (compare with Fig. 4 b). The CD spectra of the
prion protein variant E200K show that the conformation is
insensitive to addition of Cu(II) in agreement with the
FIGURE 3 X-band EPR spectra at pH 6. (a) 0.1 mM CuCl2 in a sodium
cacodylateHCl buffer. (b) 0.1 mM mPrP(23–231) with four molar equi-
valents of CuCl2. (c) 0.1 mM of E200K mPrP(23–231) with four molar equi-
valents of CuCl2. (d ) 0.1 mM of F198S mPrP(23–231) with four molar
equivalents of CuCl2. (e) 0.1 mM of D178N mPrP(23–231) with four molar
equivalents of CuCl2.
FIGURE 2 X-band EPR spectra at pH 4. (a) 0.1 mM CuCl2 in a formic
acidNaOH buffer. (b) 0.1 mMmPrP(23–231) with four molar equivalents of
CuCl2. (c) 0.1 mM of E200K mPrP(23–231) with four molar equivalents
of CuCl2. (d ) 0.1 mM of F198S mPrP(23–231) with four molar equiva-
lents of CuCl2. (e) 0.1 mM of D178N mPrP(23–231) with four molar
equivalents of CuCl2. ( f ) 0.1 mM of H177S mPrP(121–231) with four
molar equivalents of CuCl2.
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behavior of the wild-type protein (see Supplementary
material).
At pH 4, the EPR spectrum of Cu(II)-bound F198S differs
from the one observed for the Cu(II)-bound mPrP(23–231)
(comparison of Fig. 2, b and d). Apart from the Cu(II)/buffer
signal, the spectrum of a new Cu(II) complex is visible
(complex 6). The EPR parameters of complex 6 can be
determined after subtraction of spectrum 2 a from spectrum 2
d (Fig. 2, Table 1). The values agree with a ligation to one
nitrogen and three oxygens (1N3O), two nitrogens and two
oxygens (2N2O), or three nitrogens and one oxygen (3N1O)
(Peisach and Blumberg, 1974). These values clearly deviate
from those of complexes 1 and 2. At pH 6, only one Cu(II)
complex is observed for the F198S mutant (Fig. 3 d; Table 1,
complex 7). The EPR parameters are again in agreement
with a 1N3O, 2N2O, or 3N1O coordination (Peisach and
Blumberg, 1974). At pH 7.4, complex 3 is visible in the EPR
spectrum of Cu(II)-bound F198S (Fig. 4 d ). Furthermore,
a second component similar to complex 2 is visible in the
spectrum. However, the relative ratio of the contributions of
complexes 2 and 3 is different from the one observed for the
wild-type protein. Because complex 2 was not observed for
the mutant at pH values of 4 and 6, it is possible that the
copper coordination site 2 observed for F198S at pH 7.4 is
similar but not exactly the same as the one observed in the
wild-type protein (hence the question mark in Table 1).
Furthermore, the CD spectra show that the Cu(II) binding
has no substantial inﬂuence on the protein conformation (see
Supplementary material).
The full-length D178N mutant of the murine prion protein
is found to aggregate at pH 7.4 both in the presence and
absence of copper. At pH values of 4 and 6, the EPR spectra
and CD spectra of Cu(II)-bound D178N are the same as
those of the Cu(II)-coordinated wild-type protein (Figs. 2 e
and 3 e, and Supplementary material).
Stability of H177S, H187S, and H140S
mPrP(121–231) with and without copper
Comparison of the CD spectra of 10 mM of the histidine
mutants (Fig. 1 a) and of the wild-type mPrP(121–231) at pH
4 (not shown) indicates that the variants are not properly
folded at this pH value in 10 mM formic acidNaOH buffer.
Accordingly, no Cu(II) binding to the protein was found by
EPR. The EPR spectra of all histidine variants after addition
of Cu2þ is equal to that of the Cu(II)-buffer complex as is
shown in Fig. 2 f for the H177S mutant (compare with Fig. 2
a). This indicates that the protein conformation is essential
for the binding of copper to the prion protein at this pH.
Already in the presence of one molar equivalent of Cu2þ,
strong aggregation of all the histidine variants (0.1 mM)
occurred at pH 6 in 10 mM cacodylateHCl buffer.
At pH 7.4, the H140Smutant is soluble even upon addition
of four molar equivalents of CuCl2. The EPR spectrum shows
a clear contribution of complex 3 (Fig. 4 e). Furthermore, a
small contribution of complex 2 is found (see ampliﬁcation
in low-ﬁeld area of spectrum in Fig. 4 e). The H177S mutant
aggregates immediately upon addition of even one molar
equivalent of Cu2þ. Although the H187S variant also
aggregates in the presence of one molar equivalent of Cu2þ,
the aggregation process is found to be much slower than for
the H177S mutant. The EPR spectrum of the Cu(II)-bound
H187S obtained by freezing the sample after addition of
CuCl2 and before visual protein aggregation had set in shows
the characteristic features of complex 3 (Fig. 4 f ). We cannot
exclude, however, that aggregation was already in process
and the data should be interpreted cautiously.
FIGURE 4 X-band EPR spectra at pH 7.4. (a) 0.1 mM CuCl2 in a
MOPSNaOH buffer. (b) 0.1 mM mPrP(23–231) with four molar equi-
valents of CuCl2. (c) 0.1 mM of E200KmPrP(23–231) with four molar equi-
valents of CuCl2. (c9) Simulation of (c) using parameters of complex 2 in
Table 1. (d ) 0.1 mM of F198S mPrP(23–231) with four molar equivalents of
CuCl2. (e) 0.1 mM of H140S mPrP(121–231) with four molar equivalents of
CuCl2. (f ) 0.1 mM of H187S mPrP(121–231) with one molar equivalent
of CuCl2.
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Equilibrium-folding transition experiments
For the recombinant mPrP(121–231) wild type and mutants
D178N, F198S, and E200K, measurements at pH 4.0 in the
presence and absence of 50 mM NaCl were done and
compared to the previous results found for the same proteins
at pH 7 in the absence of salt (Liemann and Glockshuber,
1999). The thermodynamic parameters are reported in
Table 2. The thermodynamic stability of mPrP(23–231)
and mutants D178N, F198S, and E200K was analyzed at pH
4.0 (Fig. 5) and at pH 7.0 in the absence and presence of 135
mM NaCl. The corresponding thermodynamic parameters
are reported in Table 3.
The folding was found to be a reversible process for all the
mutants at both pH values. In general, the mutant E200K is
found to be almost as stable as the wild-type protein under all
conditions tested. The mutants D178N and F198S, which
were previously found to show a reduced intrinsic stability
at pH 7.0 for the mPrP(121–231) variants (Liemann and
Glockshuber, 1999), are also less stable than the wild-type
protein at both pH 7.0 and 4.0 in the case of the full-length
mutants. The thermodynamic stability of the C-terminal
domain alone, mPrP(121–231), and the full-length protein
mPrP(23–231) for the wild type as well as for the mutants is
approximately the same.
A major change in folding and stability of all the proteins
investigated is observed by increasing the ionic strength at
acidic pH (Fig. 5, b and c), and the formation of the folding
intermediate described previously (Hornemann and Glock-
shuber, 1998; Cereghetti et al., in preparation) is also found
for the mPrP variants under study. No determination of DGo
can be obtained, because of the concentration dependence of
the formation of the PrPSc-like folding intermediate and the
fact that the oligomeric state of this intermediate is unknown.
In summary, as shown in Tables 2 and 3, even at acidic pH
values, the thermodynamic stability data indicate that the
mutants investigated are not uniformly destabilized with
respect to the wild type.
Interestingly, the mPrP(23–231) variants D178N and
F198S are found to aggregate at pH 7.0 where no unfolding
intermediate is found for the wild-type protein. This
aggregation is most likely unspeciﬁc and is attributable to
the decreased stability of the variants with respect to the wild
type at neutral pH. On the other side, no aggregation of these
two mutant proteins is observed at pH 4 and at an ionic
strength [100 mM, i.e., under the conditions where the
unfolding intermediate is formed in the wild-type PrP(23–
231). The soluble intermediate may therefore be a precursor
of PrPSc analogous to the one formed during unfolding of
wild-type mPrP(23–231). The intermediate formation occurs
at pH 4.0 and in the presence of 165 mM ionic strength at the
same urea concentration for all the mutants as was observed
for the wild type. Indeed, at 3.5 M urea, an intermediate state
with CD spectra identical to the one of the wild type and
reminiscent of PrPSc is found. It seems therefore that the
oligomeric unfolding intermediate is also populated in the
case of the variants related to prion diseases. No intermediate
formation is found at ionic strengths\50 mM.
TABLE 1 EPR parameters of the type-2 Cu(II) complexes observed in copper-containing full-length mPrP(23–231) and its mutants
F198S, D178N, and E200K and in the mPrP(121–231) mutated forms H140S and H187S
Complex g? (60.005) gk (60.005) A? (610 MHz) Ak (610 MHz) Observed in pH
1 2.068 2.332 12 452 mPrP(121–231)* 3–6
mPrP(23–231)* 4, 6
D178Ny 4, 6
E200Ky
2 2.068 2.295 20 457 mPrP(121–231)* 3–8
mPrP(23–231)* 4, 6
D178Ny 4, 6, 7.4
E200Ky 7.4
F198S (?)y 7.4
H140Sy
3 2.055 2.230 50 495 mPrP(121–231)* 7–8
mPrP(58–91)* 7.4
mPrP(23–231)* 7.4
F198Sy 7.4
H140Sy
H187Sy
4 2.055 2.270 50 520 mPrP(58–91)* 6, 7.4
5 2.114 Not resolved mPrP(23–231)*
([4 equiv. Cu2þ)
4, 6
6 2.058 2.320 35 480 F198Sy 4
7 2.061 2.295 10 510 F198Sy 6
Hyperﬁne data are given for 63Cu.
*Data from Cereghetti et al., 2001.
yData obtained in present study.
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DISCUSSION
General remarks
Copper binding to PrPs is a highly debated matter in PrP
research. Apart from the extensive discussions on the
possible involvement of copper in the in vivo function of
PrPC or in the interconversion between PrPC and PrPSc
(Brown et al., 1997; Pauly and Harris, 1998; Wadsworth
et al., 1999; Thompson et al., 2000; Waggoner et al., 2000),
there is still no general consensus on the interpretation of
biophysical experiments concerning the in vitro copper
binding of prion proteins.
All physicochemical experiments performed up to now
conﬁrm that Cu(II) can bind at pH values[5 to the octarepeat
peptide part of the N-terminal region of PrPC (Hornshaw,
McDermott, andCandy, 1995; Hornshaw et al., 1995; Sto¨ckel
et al., 1998;Viles et al., 1999;Miura et al., 1999;Whittal et al.,
2000; Aronoff-Spencer et al., 2000; Cereghetti et al., 2001;
Jackson et al., 2001; Kramer et al., 2001; Burns et al., 2002;
Qin et al., 2002). Raman and EPR measurements show that
different pH-dependent copper-binding modes occur (Miura
et al., 1999; Aronoff-Spencer et al., 2000; Cereghetti et al.,
2001). However, there is still no agreement on the number of
Cu(II) ions that are bound nor on the binding afﬁnity (Kd
values of 1014 M up to several micromoles are reported;
FIGURE 5 (a) Unfolding transitions of mPrP(23–231) at pH 4 and at an ionic strength of 30 mM (228C). Protein concentration, 28 mM. mPrP(23–231) wild
type (d), variant E200K (m), variant F198S (.), and variant D178N (n). (b) Unfolding transitions of mPrP (23–231) at pH 4 and at an ionic strength of 165 mM
(228C). Protein concentration, 28 mM. mPrP(23–231) wild type (d) and variant E200K (m). (c) Unfolding transitions of mPrP (23–231) at pH 4 and at an ionic
strength of 165 mM (228C). 14.5 mM mPrP(23–231) wild type (d), 20 mM mPrP(23–231) F198S (.), and 20 mM mPrP(23–231) D178N (n).
TABLE 3 Thermodynamic stability of mPrP(23–231) wild type
and variants at pH 7 and 4 (228C) at different ionic strengths
DG8
(kJ/mol)
DDG8
(kJ/mol)
Cooperativity
of folding
(kJ/mol M)
[urea]1/2
(M)
pH ¼ 4.0
Ionic strength ¼ 30 mM
[NaCl] ¼ 0
Wild type 17.3 6 0.6 4.9 6 0.2 3.53
E200K 16.4 6 0.6 0.9 6 1.2 5.2 6 0.2 3.15
F198S 9.5 6 0.2 7.8 6 0.8 3.8 6 0.1 2.50
D178N 9.4 6 0.2 7.9 6 0.8 4.0 6 0.1 2.35
pH ¼ 7.0
Ionic strength ¼ 80 mM
[NaCl] ¼ 0
Wild type 25.6 6 1.6 4.2 6 0.3 6.09
E200K 25.3 6 1.7 0.3 6 3.3 4.4 6 0.3 5.75
F198S *
D178N *
pH ¼ 7.0
Ionic strength ¼ 215 mM
[NaCl] ¼ 135 mM
Wild type 26.4 6 1.7 4.4 6 0.3 6.00
E200K 27.4 6 1.5 1 6 3.2 4.9 6 0.3 5.59
F198S *
D178N *
*Could not be evaluated quantitatively due to partial aggregation during the
transition.
TABLE 2 Thermodynamic stability of mPrP(121–231)
wild-type and variants at pH 4 and 7 without NaCl
DG8
(kJ/mol)
DDG8
(kJ/mol)
Cooperativity
of folding
(kJ/mol M)
[urea]1/2
(M)
pH ¼ 4.0;
Ionic strength ¼ 30 mM*
Wild type 16.9 6 1.4 5.0 6 0.4 3.4
E200K 17.6 6 1.0 0.7 6 2.4 5.5 6 0.3 3.2
F198S 12.2 6 1.1 4.7 6 2.5 4.3 6 0.3 2.8
D178N 12.0 6 0.9 4.9 6 2.3 4.5 6 0.3 2.7
pH ¼ 7.0y;
Ionic strength ¼ 80 mM*
Wild type 29.7 6 1.0 4.8 6 0.2 6.2
E200K 29.1 6 1.5 0.6 6 2.4 4.9 6 0.3 5.9
F198S 19.4 6 0.8 10.3 6 1.7 4.4 6 0.2 4.5
D178N 22.5 6 0.8 7.2 6 1.7 4.7 6 0.1 4.8
*In the absence of NaCl.
yData from Liemann and Glockshuber, 1999.
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Hornshaw, McDermott, and Candy, 1995; Hornshaw et al.,
1995; Sto¨ckel et al., 1998; Viles et al., 1999; Miura et al.,
1999; Whittal et al., 2000; Aronoff-Spencer et al., 2000;
Jackson et al., 2001; Kramer et al., 2001). These discrepancies
are probably due to the different experimental conditions used
(such as the pH values and the model of PrP fragment
analyzed) as well as buffer artifacts as previously highlighted
(Cereghetti et al., 2001).
More recently, Cu(II) binding was observed also upstream
of the octapeptide repeat region and in the C-terminal
structured region (Cereghetti et al., 2001; Jackson et al.,
2001; Kramer et al., 2001; Hasnain et al., 2001; Qin et al.,
2002). Here we analyze by EPR the Cu(II) binding to some
point-mutation variants of the recombinant murine PrP(23–
231) related to inherited TSE forms in humans (Fig. 1 a). The
fact that the EPR spectra of the Cu(II)-bound prion proteins
were found to change for different point mutations in the
C-terminal part proves that the already previously observed
Cu(II) complexes in the EPR spectra of the C-terminal
domain PrP(121–231) can be related to speciﬁc binding
sites in the protein. Furthermore, the EPR spectra of the
improperly folded mPrP(121–231) H140S, H177S, and
H187S mutants with added Cu(II) at pH 4 (Fig. 2 f ) lacked
the characteristic features of the Cu(II)-bound mPrP(121–
231) and mPrP(23–231), which proves that a correct protein
folding is absolutely essential for Cu(II) binding at low pH
values.
Cu(II) binding to the recombinant mPrP(23–231)
wild type
In our earlier EPR results (Cereghetti et al., 2001; Van
Doorslaer et al., 2001), we showed that both the full-length
prion protein mPrP(23–231) and the C-terminal fragment
mPrP(121–231) have similar binding of Cu2þ ions from pH
values $3, whereas the N-terminal part, mPrP(58–91), only
binds at pH values [5 (Table 1). Furthermore, the Cu(II)
coordination type observed for mPrP(58–91) at pH 6
(complex 4, Table 1) differs from the binding types observed
for mPrP(23–231) and mPrP(121–231). Based on this
evidence, complexes 1 and 2 observed in the EPR spectra
of the Cu(II)-bound, full-length, wild-type prion protein
(Figs. 2 b, 3 b, and 4 b) could be assigned to binding sites in
the structured C-terminal part of the protein. Pulse EPR and
electron-nuclear double resonance (ENDOR) investigations
showed that one of the binding ligands in complex 2 is
histidine and that no nitrogen is directly coordinated to the
copper in complex 1 (Van Doorslaer et al., 2001). Complex
3-type contributions were found in the EPR spectra of
Cu(II)-containing mPrP(23–231), mPrP(121–231), and
mPrP(58–91) at pH values $7 (Fig. 4 b). In view of the
recent observation of a Cu(II) binding site outside the
octarepeat region involving His-96 and His-111 (Jackson
et al., 2001), our ﬁndings indicate that at least three binding
sites with similar EPR parameters are present in the full-
length protein. It should be noted that due to the broad line
width of the EPR spectra, small differences in the EPR
parameters cannot be detected. The sites are therefore most
likely to be similar but not identical. Pulse ENDOR
measurements indicated that more than one nitrogen atom
is directly bound to the copper ion, and similarities between
the g and copper hyperﬁne values of complex 3 and those of
known 1:2 Cu-peptide complexes in alkaline solutions
(Szabo´-Pla´nka et al., 1989) suggested that deprotonated
backbone nitrogens can be involved in the binding. Due to
the fact that the same type of Cu(II) binding was found in
mPrP(23–231), mPrP(121–231), and mPrP(58–91), involve-
ment of the N-terminal amino group could not be ruled out
(Cereghetti et al., 2001). We therefore plan to check this
possibility by putting an acetyl group on the N-terminus.
Furthermore, upon addition of more than four molar
equivalents of Cu2þ to mPrP(23–231) at pH 4 or 6, a broad
signal was observed (complex 5, Table 1) which could be
ascribed to unspeciﬁc binding of the Cu(II) ions to the
protein (Cereghetti et al., 2001).
The present CD measurements on the recombinant
mPrP(23–231) wild type in the absence and presence of up
to 10 molar equivalents of Cu(II) at pH values of 4.0, 6.0, and
7.4 show that no substantial conformational change takes
place upon addition of copper (see Supplementary material),
which indicates that the N-terminal region still remains
unstructured also in the presence of bound Cu(II). This is
contrary to earlier speculations that the N-terminal region
becomes structured upon binding, perhaps assuming an a-
helixlike secondary structure (Viles et al., 1999; Sto¨ckel et al.,
1998; Wong and Clive et al., 2000; Wong and Venien-Bryan
et al., 2000). This agrees, however, with recent molecular
modeling computations which showed that although metal
binding to the repeat region would render this region more
compact than in the apoprotein, it would not lock it into any
single rigidly deﬁned conformation (Jackson et al., 2001).
Which histidine is involved in complex 2?
To test directly which histidine of the C-terminal part is
involved in the copper binding site 2, the mPrP(121–231)
mutants H177S, H187S, and H140S were expressed (Fig. 1
a). At pH 4, none of the peptides were properly folded even
in the absence of copper as shown by CD spectroscopy, and
at pH 6, all the mutants aggregated upon addition of copper.
Because H177S mPrP(121–231) aggregated also upon
addition of copper at pH 7.4, no direct veriﬁcation of the
involvement of His-177 could be done. However, the EPR
spectra of the Cu(II)-bound D178N and of the Cu(II)-bound
wild-type prion protein at pH values of 4 and 6 are identical
(compare Figs. 2 b and 3 b and 2 e and 3 e). This indicates
that His-177 is not involved in complex 2. The change from
aspartic acid to asparagine will modify the environment of
His-177 considerably (removal of salt bridge between Asp-
178 and Arg-164 (Riek et al., 1997; Zuegg and Gready,
1992 Cereghetti et al.
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1999)), which should lead to a change in the EPR spectrum
2. Furthermore, recent MALDI-time-of-ﬂight experiments
on Cu(II)-bound human PrP failed to detect involvement of
H176 (Qin et al., 2002), which conﬁrms our present ﬁnding.
At pH 7.4, the mPrP(121–231) H140S variant did not
aggregate upon addition of one tofour molar equivalents
of Cu2þ. Besides complex 3, the EPR spectrum of complex
2 is visible (Fig. 4 e). The observation of complex 2 seems
to rule out the participation of His-140 in this binding site.
The intensity ratio of spectrum 2 to 3 is smaller for the
mPrP(121–231) H140S variant than for the full-length
mPrP(23–231) wild type, but is similar to the one found
for the wild-type mPrP(121–231) fragment (Cereghetti et al.,
2001). This may indicate that the copper afﬁnity at site 2
decreases when the mPrP(23–120) part is missing.
Only the possible involvement of His-187 in complex 2
remains (Fig. 1 b). Indeed, no contribution of complex 2 is
found in the EPR spectrum of mPrP(121–231) H187S after
addition of one molar equivalent of copper at pH 7.4 (Fig.
4 f ). Owing to the slow aggregation of mPrP(121–231)
H187S upon addition of copper, this observation should be
interpreted with caution.
Additional indications for a His-187-copper bond can be
found in the observation that the EPR spectra of the Cu(II)-
bound mPrP(121–231) F198S variant are different from
those of the Cu(II)-bound mPrP(23–231) wild type. Pre-
vious studies showed that the replacement F198S strongly
destabilizes the prion protein. The hydrophobic phenyl-
alanine residue buried in the hydrophobic core of the protein
in the region between helices 2 and 3 is replaced by the
nonhydrophobic residue serin and possibly induces local
structural rearrangements within the protein scaffold (Riek
et al., 1998; Liemann and Glockshuber, 1999). These re-
arrangements within the C-terminal domain might
dislocate the Cu(II) ligands within the region where
complexes 1 and 2 are formed. If His-187 is responsible
for Cu(II) binding leading to the features of complex 2, the
fact that this residue comes in the near vicinity of the site
of mutation at position 198 in the three-dimensional fold
could explain the absence of complex 2 due to an altered
environment of His-187 (Fig. 1). Histidine residues 177 and
140 are at a larger distance from residue 198 (Fig. 1 a). The
fact that new types of Cu(II) complexation are observed at
these pH values (complexes 6 and 7), for which the EPR
parameters support nitrogen involvement in the direct
ligation of the copper, would indicate that His-187 is still
binding to the copper ion but that the binding environment
has changed. Different potential additional ligands for
Cu(II) are present in the vicinity of His-187 (Fig. 1 b). The
new binding environment has also become strongly pH
dependent (change of complex 6 to 7). At pH 7.4, a
contribution similar to that of complex 2 is observed for
the Cu(II)-bound mPrP(23–231) F198S variant. This might
be explained in two ways. Because the observed complexes
in the wild type and the mutant at pH 7.4 are only similar
within the error of the EPR measurement, they may have
slightly different local symmetries. On the other hand, it is
possible that the same complex as in the wild-type protein
is observed, but that due to the mutation and consequent
change in the local structure, its formation is only possible
at a higher pH value. This might be the case if in the wild-
type protein the different copper ligands are forced together
by sterical effects that facilitate copper ligation, whereas in
the mutant, the ligands are no longer at a favorable position
and a higher pH value (i.e., deprotonation of the ligands) is
needed to enable the complex formation.
Finally, at pH 4 and 6, the spectra of the Cu(II)-bound
E200K mutant look the same as those of the Cu(II)-bound
wild-type protein (Figs. 2 c and 3 c), and complex 2 is found
in the EPR spectrum of the Cu(II)-coordinated mutant at pH
7.4. Because residue 200 is not in the vicinity of His-140,
His-177, or His-187 (Fig. 1 a), this does not contradict our
earlier pulse-EPR results that one of these histidines is
involved in complex 2 (Van Doorslaer et al., 2001).
How to interpret complex 3?
As mentioned before, complex 3-type binding was found
in mPrP(23–231), mPrP(121–231), and mPrP(58–91) (Cere-
ghetti et al., 2001). Because of the resemblance between the
EPR parameters of complex 3 and those of Cu(II)-peptide
complexes that involve coordination to deprotonated back-
bone nitrogens and end-amino groups, it was not clear to
which part of the full-length protein the copper-binding site 3
could be ascribed, and the possibility of spurious binding to
one or all of the studied peptides had to be taken into
account. Interestingly, we now observe that complex 3 is not
formed in the Cu(II)-bound mPrP(23–231) E200K variant
(Fig. 4 c), whereas it is found for the mPrP(121–231) H140S
and H187S and the mPrP(23–231) F198S variants (Fig. 4, e,
f, and d, resp.). The E200K mutation is situated at the
beginning of the third a-helix of the C-terminal part and is
located at the surface of the protein (Riek et al., 1998). The
disappearance of the contribution of complex 3 in the
spectrum of Cu(II)-bound E200K links the formation of this
complex in the full-length protein to a binding site around
residue 200 in the C-terminal part. It seems to exclude that
this complex is the same as is observed in Cu(II)-bound
mPrP(58–91), because this region is not affected by the point
mutation. This also agrees with the fact that for the F198S
variant, the spectral intensity of 2 is larger than that of 3,
whereas this is the inverse in mPrP(23–231) wild type.
Residue 198 is near to residue 200 (Fig. 1 a) and the F198S
mutation might already hinder formation of complex 3 due to
a change in the hydrophobicity of the site.
The observation that at pH 7.4, only complex 3 is
visible in Cu(II)-bound H187S mPrP(121–231) seems to
corroborate the earlier assumption that the two C-terminal
sites 2 and 3 do not evolve into each other. Indeed, the
latter ﬁnding would indicate that the histidine ligand in
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complex 2 no longer coordinates when the site evolves into
complex 3, which seems very unlikely, because histidine
binding should be favored at higher pH values.
Where is complex 1 located?
Our earlier results (Cereghetti et al., 2001; Van Doorslaer
et al., 2001) showed that complex 1 is only found at pH
values #6, and that no nitrogens are involved in the direct
binding to the copper. This complex is found for
mPrP(23–231) D178N and for E200K, which indicates that
this copper-binding site is neither centered around residues
178 and 200 nor around residue 164 (Asp-178 forms
a hydrogen bond to Arg-164 in the wild-type prion protein
(Riek et al., 1998)) nor around residue 128 (Tyr-128—
Asp-178 hydrogen bond (Riek et al., 1998)). Complex 1 is
not formed in Cu(II)-bound F198S. This does not
necessarily mean that the binding site is centered around
residue 198. The replacement of Phe-198 in the hydropho-
bic core by Ser is a nonconservative mutation. Without
follow-up structural changes, this mutation would lead to an
empty cavity that could accommodate 2 or 3 water
molecules. In the wild-type protein, the aromatic ring is
surrounded by numerous hydrogen-bonded polar side
chains, and replacement by serine will surely modify these
polar interactions (Riek et al., 1998). One of these
interactions is the hydrogen bond between Arg-156 and
Glu-196 (Riek et al., 1998; Zuegg and Gready, 1999).
Interestingly, the NMR study of Cu(II)-bound mPrP(91–
231) at pH 6 showed a copper-binding site centered around
residues 135 and 155 upon titration above stoichiometry
(Jackson et al., 2001). Because complex 1 is still formed at
this pH, it is tempting to relate these observations. In
addition, the posttranslational glycosylation at asparagine
residues 181 and 197 could inﬂuence copper binding as
well.
Finally, the present study still does not allow us to
determine whether site 1 evolves into site 2 upon pH
increase. The fact that the EPR spectra of complexes 1 and 2
remain unchanged or are altered simultaneously upon point
mutations seems to support a relation between the two
complexes but cannot prove it beyond doubt.
Biological relevance
Relating the in vitro analytical data on Cu(II) binding to
prion proteins to the in vivo binding is difﬁcult, because PrPC
is a membrane protein. It is attached to the cell surface via
a glycosyl phosphatidylinositol anchor and is supposed to
have a high level of lateral mobility within the membrane.
This makes determination of the local protein concentration
difﬁcult. Furthermore, the prion protein might interact with
another protein at the membrane that stabilizes PrPC-Cu(II)
complexes. Nevertheless, some of our present observations
are interesting in view of the biological function.
On the one hand, the role played by the point mutations in
facilitating the process of disease formation is still not
clariﬁed. Destabilization of the three-dimensional fold of
PrPC for the mutant proteins was hypothesized as the cause
of the increased propensity of the mutants to convert to the
infectious isoform PrPSc (Prusiner, 1997; Cohen et al., 1994;
Huang et al., 1994). Studies of the thermodynamic stability
of the corresponding variants of murine PrP(121–231) at pH
7.0 (Liemann and Glockshuber, 1999) and of some variants
of human PrP(90–231) at pH 3.6–7.2 (Swietnicki et al.,
1998) excluded this possibility as a general explanation for
spontaneous prion formation in inherited TSEs as they
showed that not all of the mutants were apparently
destabilized by the point mutation. The observed urea-
induced equilibrium-folding transitions at pH values of 4.0
and 7.0 of the full-length mPrP variants D178N, F198S, and
E200K allowed us to conﬁrm that also for the full-length
protein and even under acidic pH conditions, no uniform
destabilization of the mutated proteins is observed (Tables 2
and 3). Acidic conditions are found in the endocytic
pathway, where the PrPC to PrPSc conversion is supposed
to take place (Lee et al., 1996; Hornemann and Glockshuber,
1998). Furthermore, the dependence of intermediate forma-
tion on the protein concentration appears to vary for the
different protein variants. The D178N variant of PrP(23–
231) already presents a strongly populated intermediate at
a 20 mM protein concentration (Fig. 5 c), whereas the E200K
variant shows minimal intermediate population at 3.5 M urea
even at a protein concentration of 30 mM (Fig. 5 b). This
observation prompts us to assume that the point mutation
may facilitate or hinder oligomerization of the protein on the
way to PrPSc formation. This may perhaps inﬂuence the
interaction with other factors involved in normal PrP
metabolism if temporary oligomerization plays a functional
role in the cell.
On the other hand, the ﬁnding that PrP is able to bind
Cu(II) in vivo (Brown et al., 1997) prompted the suggestion
that Cu(II) is involved in the biological function of the prion
protein, although the subject is still highly controversial. The
recent ﬁndings that the C-terminal part of the prion protein
can bind Cu(II) (Thompson et al., 2000; Kramer et al., 2001;
Cereghetti et al., 2001; Van Doorslaer et al., 2001; Jackson
et al., 2001) are important in view of the fact that the
known pathogenic mutations take place in the PrP(102–238)
part of the protein (Collinge, 2001) and in view of the obser-
vation that metal-bound active centers are usually located in
the structured region of a protein, where the coordina-
tion partners are stabilized by the protein scaffold. The CD
measurements show that copper induces no substantial
conformational changes in the recombinant mPrP(23–231)
wild type nor in its variants (see Supplementary material), so
that it seems unlikely that the N-terminal part gains a ﬁxed
structure as suggested earlier (Viles et al., 1999; Sto¨ckel
et al., 1998; Wong and Clive et al., 2000; Wong and Venien-
Bryan et al., 2000).
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In vitro experiments on the Cu(II) binding of prion
proteins are evidently important to understand the in vivo
Cu(II)-related behavior, but the in vitro Cu(II) binding of the
protein can also be seen as a sensor for the local protein
structure. The differences in the in vitro Cu(II) binding
between the mPrP(23–231) variants D178N, F198S, and
E200K, which correspond to three different phenotypes of
inherited prion diseases in humans, and the wild-type protein
as detected by EPR are necessarily related to changes in the
local structure of the protein.
Our present results strongly suggest that His-187 is
involved in the binding site 2 found in mPrP(23–231) wild
type. This is interesting in view of a number of earlier
observations.
First of all, PrP(178–193) was found to promote Cu(II)-
induced lipid peroxidation and cytotoxicity in primary
neuronal cultures, whereas PrP(144–154) and PrP(198–
218) had no effect on the Cu(II) toxicity (Thompson et al.,
2000). There was no increase in toxicity induced by
PrP(178–193) in cultures treated with Fe(II) or hydrogen
peroxide, indicating a preferential modulatory effect on
Cu(II) toxicity by PrP(178–193). His-187 is centered well
within this protein segment.
Recently, an inherited prion-related encephalopathy re-
sembling the GSS disease was discovered and associated
with the H187R mutation (Cervenakova et al., 1999;
Buteﬁsch et al., 2000). This is the only known histidine
mutation associated with familial encephalopathy, and for
this mutation, complex 2 formation would clearly be
impossible. It is interesting to point out that also the F198S
mutant associated with the GSS disease did not form
complex 2 upon addition of copper at a lower pH. Even if
the copper-binding capacity of the prion protein has no
biological meaning, Cu(II) can be seen as a sensor to detect
local changes in the protein upon mutations. The copper-
binding behavior of the two mutants H187R and F198S
related with the same phenotype of prion diseases in humans
shows that both mutations cause local structural changes
around residue 187. The latter could also explain why
Forloni et al. (1999) found no marked difference in the
neurotoxicity of the PrP(195–213) wild type and F198S
mutated segment. This segment is missing the region around
residue 187. A comparative NMR analysis of H187R,
F198S, and other mutants associated with the GSS
phenotype would therefore be very interesting.
The fact that the mutation E200K causes the inherited
form of CJD is still puzzling. The NMR structure shows that
the mutation is located on the protein surface (Fig. 1 a) and
predicts that even the change in overall charge of the protein
should not have a major impact on the global structure.
Indeed, the thermodynamic stability of the E200K variant
is similar to that of the wild-type protein (Table 3).
Interestingly, our present study shows that the mPrP(23–
231) E200K mutant shows a marked difference in its copper
binding at pH 7.4 (complex 3 is missing from the EPR
spectrum). In this view, the recent analysis of the metal
occupancy both of the brains and of the PrP of patients with
sporadic CJD is interesting (Wong et al., 2001). The authors
found an increase of manganese and, to a lesser extent, of
zinc accompanied by signiﬁcant reduction of copper bound
to the puriﬁed PrP of all sporadic CJD variants. The latter
reduction gives an interesting link to the observation that at
neutral pH, complex 3 is missing from the EPR spectra of
Cu(II)-bound E200K, the point mutation leading to the
inherent form of CJD.
The mPrP(23–231) D178N variant shows similar copper-
binding behavior at pHvalues #6 as the wild-type prion
protein, but it is found to aggregate at pH 7.4 both in the
absence and presence of copper. Reduced stability of D178N
peptide segments in the absence of copper has also been
reported earlier. mPrP(121–231) D178N could not be ob-
tained in soluble form in the periplasm and showed reduced
thermodynamic stability (Liemann and Glockshuber, 1999).
Turbidimetric analyses indicated an increase in the ag-
gregating capacity of PrP(169–185) D178N in comparison
to the wild-type peptide segment (Forloni et al., 1999). The
human PrP(90–231) D178N mutant was found to aggregate
in the inclusion bodies of E. coli (Swietnicki et al., 1998).
This all agrees with the NMR prediction and molecular
dynamics simulations that the D178N mutation removes the
salt bridge between Asp-178—Arg-164, which will thermo-
dynamically destabilize the mutant (Riek et al., 1998; Zuegg
and Gready, 1999). Furthermore, Asp-178 is in close
proximity to the S—S bridge. A mutation in this region
may potentially interfere with the disulﬁde-bridge formation.
Our ﬁndings show that in vitro, the main difference between
the wild type and the mutant lies in the self-aggregation at
pH 7.4 and not in the copper-binding behavior.
In conclusion, this study shows that protein destabilization
alone cannot account for the spontaneous pathogenic activity
of all the known mutations. The change observed in the in
vitro Cu(II) binding behavior of the mPrP(23–231) variants
E200K and F198S opens the possibility that protein
destabilization and altered Cu(II) binding behaviors are
responsible for the pathological effects, and that the interplay
between them might be related to the phenotype of the
different prion diseases.
This study thus opens the way to future experiments to
unravel further the Cu(II) binding sites and their biological
meaning in prion proteins. The involvement of the N-ter-
minal amino group in complex 3-type binding sites should be
tested by putting an acetyl group on the N-terminus.
Furthermore, the Cu(II) binding site involving His-96 and
His-111 (Jackson et al., 2001) should be addressed in a future
study by the analysis of the EPR spectra of full-length mPrP
and of its speciﬁc His-96/His-111 mutants. Finally, to
determine a possible relationship between speciﬁc patholog-
ical effects and altered Cu(II) binding and/or protein
destabilization, a larger number of prion mutants should be
studied.
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